April 6, 2021 05:09 PM EDTUpdated April 9, 03:30 PM
R&D
FDA+

Fi­bro­Gen shares take a beat­ing as CEO re­veals safe­ty da­ta ma­nip­u­la­tion for its block­buster con­tender rox­adu­s­tat

John Carroll

Editor & Founder

Fi­bro­Gen $FGEN back­tracked on some of the key safe­ty da­ta used to boost hopes for their ane­mia drug rox­adu­s­tat, elim­i­nat­ing its claim of su­pe­ri­or­i­ty over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times